Objectives: Hospitalized patients often experience adverse events of the gastrointestinal tract due to analgesic treatment. The objectives of this study were to estimate use of medications for treatment of nausea, vomiting, or constipation (NVC medications) after initiation of analgesic treatment, and to compare differences in length of stay and treatment costs between patients who received NVC medications and those who did not.
A n estimated 34.9 million patients are hospitalized annually, with roughly 43% to 77% of patients experiencing pain during their stay as a result of their disease and physical condition. [1] [2] [3] [4] [5] Hospitalized patients often receive opioid analgesics, nonopioid analgesics, or both to relieve symptoms associated with pain. Adverse events due to analgesic treatment are common, mainly in the gastrointestinal tract [eg, nausea, vomiting, or constipation (NVC)] or central nervous system (eg, somnolence, headache, pruritus). [5] [6] [7] Gastrointestinal adverse events can be particularly bothersome to hospitalized patients after the initiation of analgesic therapy. Studies have shown that 10% to 50% of patients receiving opioids experience nausea/vomiting, which in many studies is the most common adverse event reported after analgesic initiation. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Constipation also occurs often after analgesic therapy, but may be less frequent (15% to 41% of patients) and takes a longer time to develop than nausea/vomiting. [9] [10] [11] [12] [13] [14] The prevalence of NVC is influenced by the class of analgesic that is prescribed; patients receiving opioid analgesics typically experience more NVC than patients receiving nonopioid analgesics. [18] [19] [20] These adverse events can be debilitating and frequently increase length of hospital stay and treatment costs for patients. In one study, administration of NVC medications for opioid-induced nausea/vomiting in surgical patients was reported to increase hospitalization by 0.47 days, with an attributable $510 increase in cost. 21 A study that compared the differences in costs in cancer patients with versus without constipation found that constipation was associated with a significant increase in various types of costs including total, inpatient, laboratory, and pharmacy costs. Inpatient costs for cancer patients with constipation were higher by 131.9% than those without constipation. 22 Further study is necessary to estimate the incidence and economic consequences of NVC with analgesic administration in a hospitalized population composed of patients with different comorbidities receiving analgesic treatment of differing dosage forms (oral vs injectable). This study was conducted to investigate use of NVC medications in hospitalized patients after initiation of analgesics and to determine which factors significantly influence use of NVC medications. This study also compared total treatment costs and length of stay between hospitalized patients who received NVC medications versus those who did not.
episode: admission and discharge dates and status; length of hospital stay; diagnosis and procedure codes; and itemized billing information for procedures, laboratory tests, and drug therapy.
The diagnosis and procedure for each patient were provided using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Patients were linked at the hospital/medical record number level to track across multiple visits to a hospital. An individual patient could be included more than once in the study if that patient was admitted from a hospital (or health care system) to another hospital (or health care system) during the study period.
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Study Patients
Data were collected from January 1, 2005 to December 31, 2007 . Patients hospitalized between July 1, 2005 and June 30, 2007 were included in the study cohort if they were 18 years or older at the time of admission, and were recorded as having received a prescription for an opioid or nonopioid analgesic during hospitalization. Patients who received a prescription for nonopioid analgesics that can be used for multiple indications, such as therapeutic classes of salicylates or analgesics/antipyretics, were excluded from the study cohort (Table 1) . Patients who had no health insurance coverage during the study period, natural childbirth, human immunodeficiency virus infection, organ or tissue transplantation surgery, or who were discharged/transferred to other hospitals were also excluded from the study. In addition, to stratify the study patients into 4 groups after minimizing confounding effects from the different therapeutic classes and dosage forms of analgesics, the following patients were excluded: those who received combination analgesics containing an opioid and an nonopioid, or received an opioid concomitantly with a nonopioid analgesic on the initiation date as well as patients who received NVC medications during the 6-month period before the admission.
Eligible patients were divided into 4 mutually exclusive groups based on therapeutic class (opioid vs nonopioid) and dosage form (oral vs injectable) of the first analgesic prescribed/administered by any unit of the hospital (eg, operating room, postanesthesia care unit, etc). 27 The opioid group included patients who received either opioid agonists or opioid partial agonists, which have long been used to treat acute pain such as postoperative pain. 6, 27 Patients who used an epidural were classified as an injectable opioid analgesic user. The nonopioid group included patients who received nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors, which are typically used for mild to moderate pain. 6, 27 Study Design This cohort study followed eligible patients for 14 days from the date of the first prescription for an analgesic after admission until (1) the date of switching to a different analgesic, (2) the first date of NVC medication use, or (3) the date of discharge, whichever occurred first. The 14-day restriction was applied based on conservative estimation of time to develop an adverse event and medication half-life. Opioid-related nausea/vomiting usually develops within 7 to 10 days from the initial use of opioid analgesics 28 and methadone has the longest half-life among opioids (47 h) and needs approximately 14 days to be eliminated from the body. 6 Among major adverse effects of analgesics, gastrointestinal adverse events such as NVC were the focus of this study. Because the event rate of these symptoms may be underreported or may not be recorded at all in the inpatient setting, use of ICD-9-CM codes for NVC may underestimate these events. Therefore, this study examined the use of NVC medications as a proxy for NVC events. As patients who experience NVC often need to manage their symptoms, the administration of NVC medications to treat those symptoms may be a good indicator of those adverse events. 29 Medications for the treatment of nausea/vomiting included dimenhydrinate, meclizine, prochlorperazine, trimethobenzamide, alosetron, dolasetron, granisetron, ondansetron, palonosetron, aprepitant, diphenidol, dronabinol, nabilone, droperidol, chlorpromazine, perphenazine, promazine, promethazine, scopolamine, and metoclopramide. 27, 30, 31 Medications for the treatment of constipation included senna, sennosides, bisacodyl, methylcellulose, psyllium, glycerin (glycerol), sorbitol (D-glucitol), mineral oil, magnesium citrate/hydroxide, carbon dioxide-releasing suppositories, sodium phosphate, and docusate calcium/sodium.
To exclude patients who received prophylaxis for NVC, patients who received NVC medications during the 6-month period before initiation of analgesics were excluded. Patients who received medication for constipation on the first day of treatment with analgesics were also excluded. Received the study analgesic during the 6-month history period
12,652
Were discharged/transferred to another hospital
20,826
Received a different analgesic simultaneously on the initiation date
130,232
Received nausea, vomiting, or constipation medication within the 6-month history period before initiation of the study analgesics
91,885
Total study patients 434,304
*Opioid analgesics included (1) opioid agonists including codeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, opium, oxycodone, oxymorphone, propoxyphene, sufentanil, and tramadolas well as (2) opioid partial agonists such as buprenorphine, butorphanol, nalbuphine, pentazocine, and dezocine. Nonopioid analgesics included (1) nonsteroidal anti-inflammatory drugs including bromfenac, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, and tolmetin or (2) cyclooxygenase-2 inhibitors including celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, or valdecoxib. Nonopioid analgesics that can be used for multiple indications such as therapeutic classes of salicylates or analgesics/antipyretics were not included. NVC medications were classified based on the first NVC medication received after initiation of an analgesic. If a medication for the treatment of nausea/vomiting was administered on the same day or after initiation of analgesics, this medication was considered to be used for nausea/vomiting. Likewise, if a medication for the treatment of constipation was administered at least 1 day after initiation of analgesics, this medication was assumed to be used for constipation. If a patient received a medication for nausea/vomiting and proceeded to use a medication for constipation on the same day or after 1 day, the patient was classified as a recipient of both classes of medications.
The base analysis was performed with use of medications recommended for treatment of NVC as the primary outcome. Because the dates of ICD-9-CM diagnosis codes are not available in the Premier Perspective database, the ICD-9-CM diagnosis codes could not be used to detect an adverse event of NVC after initiation of analgesics. To assess the robustness of the study results, the sensitivity analyses were performed using ICD-9-CM diagnosis codes for NVC without consideration of time from initiation of analgesics to diagnosis of NVC. 32 
Statistical Analysis
Time to initiation of NVC medication use was compared between the 4 study groups with Kaplan-Meier estimates and the log rank test. 33, 34 Time to initiation of NVC medication use was defined as the duration from initiation of analgesics until the date of first use of NVC medication. Patients who did not use NVC medication were treated as censored cases at the last day of follow-up.
A Cox proportional hazards model was used to assess the effects of analgesic use on the risk of NVC medication use, adjusting for age, sex, comorbidities, surgery, and number of drugs. To adjust for the severity of the patient's health condition, the model included comorbidities such as gastrointestinal perforation, ulcer, obstruction, or bleeding (ICD-9-CM 530-579); cardiovascular disease (ICD-9-CM 410-414, 426-428, 440-442); cerebrovascular disease (ICD-9-CM 430-438); hypertension (ICD-9-CM 401-405); diabetes (ICD-9-CM 250); chronic obstructive pulmonary disease (ICD-9-CM 490-492, 496); and cancer (ICD-9-CM 140-239). The model also included variables such as the total number of prescription drugs received (in terms of therapeutic classes), and surgical procedures performed during the hospital stay (ICD-9-CM procedure codes 00-86).
The effects of NVC medication use on length of hospital stay and treatment costs were investigated. Length of stay was defined as the total days of hospitalization, and treatment costs were calculated by summing medical and drug costs during hospitalization. Expected length of hospital stay and treatment costs were estimated using a generalized linear model with log link function and g distribution, respectively, adjusting for types of initial analgesics received, age, sex, comorbidities, surgical procedures, and number of prescription drugs (ie, total number of therapeutic classes of prescription drugs administered). The generalized linear model was used because it allows multiplicative models of g-type for right-skewed data for length of hospital stay and treatment costs. 35 Differences in the expected length of hospital stay and treatment costs between patients who received NVC medications and patients who did not were tested using a t test. All costs Table 2 shows the baseline demographic and clinical characteristics of the patients when classified by their initial analgesic during hospitalization. The eligible 434,304 patients were classified into 4 mutually exclusive groups based upon the first analgesic that they received during hospitalization: oral opioid recipients (19, Opioid analgesic recipients tended to be older than nonopioid analgesic recipients (both dosage forms). Injectable opioid analgesics were administered more frequently than other analgesics in patients who underwent surgery. Table 3 presents the proportion of patients who received NVC medications after administration of analgesics during the study period. Within each of these subgroups, a higher percentage of women than men received NVC medication. More than half of the patients who received surgery in the digestive system, musculoskeletal system, or female genital/ obstetrical procedures used NVC medications, whereas about one-third of patients who had cardiovascular surgery used NVC medications.
RESULTS
The risk of receiving NVC medications varied significantly across the 4 groups (Table 4) . For patients who did not have surgery, those who received injectable opioids had a 4.8-fold greater risk of receiving NVC medication than those receiving oral nonopioids after adjustment for age, sex, comorbidities, surgery, and number of drugs. However, surgery patients receiving injectable opioid analgesics had an opposite effect (RR=0.57). Similar trends are found in patients receiving oral opioid or injectable nonopioid analgesics. Compared with nonsurgery patients who received an oral nonopioid analgesic, nonsurgery patients receiving injectable opioids had the greatest increase in risk of receiving a medication for nausea or vomiting (RR=5.80), whereas nonsurgery patients receiving oral opioids were the most likely to receive a medication for constipation (RR=1.96). Risk of receiving a medication for nausea/vomiting decreased with each decade increase in age (after age 45 years), whereas risk of receiving a medication for constipation increased over that same time span.
Patients who received an NVC medication were hospitalized longer than patients who did not receive an NVC medication, and the difference in length of stay (about a quarter of a day) was statistically significant in each group (Table 5) . Similar trends were found in expected treatment costs between patients with and without an NVC medication, with a statistically significant mean difference of $756. Patients receiving an oral opioid analgesic had the largest mean differences in length of stay and treatment costs between patients with and without NVC medication use, whereas patients receiving an injectable opioid analgesic had the smallest mean differences. Factors associated with the length of hospital stay and treatment cost are presented in Table 6 . Overall, nonsurgery patients who received an oral nonopioid analgesic stayed in the hospital longer than nonsurgery patients who received other analgesics. However, surgery patients who received an oral nonopioid analgesic had shorter hospital stay than surgery patients who received other analgesics. Increasing age was associated with an increased length of hospital stay and treatment costs respectively. Patients who had serious gastrointestinal disorders or cancer were more likely to stay in the hospital longer and had higher costs than those who did not. Surgery patients who received an oral nonopoid analgesic had lower treatment costs than surgery patients who received other analgesics.
Plots of the cumulative probabilities of NVC medication use during the 14-day follow-up period after stratification by therapeutic class of NVC medication are displayed in Figure 1 . The Kaplan-Meier estimate of the cumulative probability of receiving an NVC medication was 71.5% for at least one gastrointestinal event overall (NVC); 57.5% for nausea/vomiting, 25.1% for constipation, and 7.1% for both nausea/vomiting and constipation (P<0.005, log rank test). Figure 2 displays trends of the cumulative probabilities for NVC medication use during the follow-up period, classified by the initial analgesic received. The KaplanMeier estimate was 77.7% for injectable opioid recipients, 65.4% for injectable nonopioid recipients, 54.9% for oral opioid recipients, and 35.9% for oral nonopioid recipients (P<0.005, log rank test).
DISCUSSION
This study shows that over half of all hospitalized patients (55.1%) receiving opioid or nonopioid analgesics subsequently receive NVC medications, including medications for nausea/vomiting in 50.5%, medications for constipation in 12.4%, and medication for both nausea/ vomiting and constipation in 4.4%. An examination of the existing literature found no previous studies of NVC medication use in hospitalized patients receiving any analgesic (ie, opioid or nonopioid). However, a few studies examined use of NVC medications in cancer or elderly patients receiving opioids, and reported that 42% to 65% of patients received antiemetics for the treatment of nausea/ vomiting, whereas laxatives were administered to 55% to 87% of patients for the treatment of constipation. [36] [37] [38] Although the proportion of patients receiving medications for nausea/vomiting in this study falls within the range reported by previous studies, the rate of medication use for constipation falls below the previously reported range. This difference in constipation is likely owing to differences in the patient populations and study design. This study included data from all hospitalized patients, whereas previous studies focused on cancer patients or elderly patients receiving opioids. [36] [37] [38] Constipation increases with age and is highly prevalent (27% to 40%) in cancer patients even without opioid intervention. 37, [39] [40] [41] In addition, this study attempted to exclude all patients receiving prophylactic medications for constipation, and thus the observed rate of 12.4% theoretically represents the percentage of patients actually being treated after constipation occurs. Previous studies reporting use of laxatives did not make such a distinction; therefore, the rates of laxative use reported in previous studies may have been inflated by laxatives prescribed for prophylactic purposes. This study used NVC medication use to estimate the prevalence of NVC after administration of analgesics. Because hospitalized patients who experience adverse events often receive treatment to manage their symptoms, the administration of rescue medications to treat those symptoms should be a good indicator of those adverse events. 29 Previous studies of the adverse event incidence of NVC in hospitalized patients receiving opioids reported that 14% to 50% of patients typically experience nausea/ vomiting and 14% to 22% of patients experience constipation. [8] [9] [10] [15] [16] [17] [18] Results regarding medication usage for nausea/vomiting in hospitalized patients in this study are consistent with the adverse event incidences of previous studies (50.5% vs 14% to 50%), whereas the results regarding medication usage for constipation are slightly below the lower end of the expected range of incidence of constipation (12.4% vs 14% to 22%). It is possible that although patients may have experienced constipation, they were not treated with a laxative. In fact, a previous study reported that 27% of the patients who said they were constipated were not taking any laxatives. 42 This could be due to differences in the perceived severity by the patient or the desire to treat with nonpharmacologic methods first. Another possible contributing factor was that we excluded a large portion of patients who were treated prophylactically with laxatives before initiation of opioid therapy, although they still might develop constipation. Despite receiving prophylactic laxatives after surgery, 60% of surgical patients still developed constipation. 43 Overall, this study demonstrates that NVC medication usage can be a viable proxy for actual NVC occurrence, with any deviation in incidence owing to differences in study populations.
This study found that hospitalized patients receiving injectable analgesics were more likely to require NVC medications than patients receiving oral analgesics. A previous study found that hospitalized nonsurgical patients receiving injectable opioids reported significantly higher incidences of nausea than patients receiving oral opioids. 8 Other studies also found similar trends that nausea and vomiting occurred in about 50% of patients with injectable opioids, 16 and 10% to 40% of patients with oral opioids. [10] [11] [12] [13] [14] [15] Patients receiving injectable analgesics may experience more adverse events owing to the increased rate of absorption and higher circulating peak concentrations that occur when dosing with injectable forms. 8 Patients were more likely to receive NVC medication if they were young, female, had comorbidities such as gastrointestinal problems or cancer, or did not undergo surgery. This finding is consistent with previous results that younger and middle-aged patients reported significantly more opioid-induced adverse events than older patients, with a general trend toward a decreasing incidence of nausea with increasing age. 8, 17 Patients aged 18 to 40 years have been documented to report the highest incidences of nausea after receiving opioids, 8 and this was also found in this study when patients received opioid or nonopioid analgesics. Sex was identified as a significant risk factor for use of NVC medications; compared with male patients, female patients had a 20% higher risk of using medications wThe difference in the adjusted length of hospital stay (or treatment costs) between patients with an NVC medication and patients without an NVC medication were tested using t test.
CI indicates confidence interval; NVC, nausea, vomiting, or constipation.
for nausea/vomiting and a 35% higher risk of using medications for constipation. These results support previous findings that women experience more nausea/vomiting than men after opioid therapy, with a 60% higher risk of nausea/vomiting and a higher prevalence of constipation, as women spend 52% more time than men receiving opioids and laxatives concurrently. 17, 36 On average, hospitalized patients who received NVC medications after initiation of analgesic therapy stayed approximately a quarter day longer and had total treatment costs that were $756 higher than patients who did not receive NVC medications after starting analgesic therapy. However, it cannot be determined whether the higher treatment costs are related to the management of pain, the adverse effects of pain management, or the treatment of comorbidities. These results are similar to previous findings that hospitalized patients experiencing nausea/vomiting owing to opioid therapy stayed in the hospital 0.47 days Results of log rank test for the differences in time to medication use among nausea/vomiting, constipation, and both was p<0.0001 longer with extra treatment costs of $510, compared with patients who did not experience nausea/vomiting after opioid therapy. 21 The difference in treatment costs between the previous study and this study may be due to increases in the price of healthcare resources. The differences in length of stay may be attributed to a national trend of decreasing length of hospital stay from an average of 5.0 to 4.8 days between 1999 and 2006. 1, 44 To assess the robustness of the study results which were based on the use of NVC medications as a proxy for NVC events, the sensitivity analyses were performed to detect NVC using ICD-9-CM diagnosis codes. The event rate of NVC according to ICD-9-CM codes was highest among oral opioid recipients (5.9%), followed by injectable nonopioid recipients (4.9%), injectable opioid recipients (4.7%), and oral nonopioid recipients (2.5%). In contrast, the event rate using NVC medication administration ranged from 19.2% to 59.5%. The vast difference in percentages reported by these 2 methods is not surprising; although physicians often prescribe medications for symptomatic relief of NVC in hospitalized patients, only rarely is an ICD-9-CM code recorded for a patient with an adverse event that is neither severe nor unremitting. 45 A previous study using ICD-9-CM codes found that 5.1% to 6.1% of patients receiving oral opioids (morphine and oxycodone) had an ICD-9-CM diagnosis of constipation, 45 a rate much lower than reported in other studies based on adverse event reports of constipation after opioid use. [9] [10] [11] [12] [13] [14] To our knowledge, this is the first study to examine the incidence of medication use for analgesic-induced NVC in a large population of inpatients with various comorbid conditions. In addition, because patients in this cohort study did not receive a set regimen of analgesics or NVC medications, the study is more likely to reflect actual clinical practice. However, this study is not without its limitations, the first being inherent in its design as a nonrandomized observational cohort study. 17 It is likely that physicians select a specific analgesic after consideration of patient risk factors-such as comorbidities or concomitant medications-to minimize the incidence of NVC. This selection bias likely resulted in underestimation of NVC events, limiting determination of the independent effect of analgesics (versus other confounding factors) on NVC medication use. Caution is needed in interpreting the results.
Another limitation was the use of administrative claims data. Although the administrative claims database provided a large study population, the database may contain coding errors, documentation errors, and incomplete data that may affect data integrity-though these discrepancies would likely be equally distributed across all study cohorts. 25, 46 In addition, an administrative claims database may not contain clinical information that would have improved the study, such as the purpose of NVC medication use (ie, prophylaxis or treatment) or the date of NVC diagnosis. 25, 47 We excluded patients based on study eligibilities (listed in Table 1 ) to minimize confounding related to prophylactic use of NVC medications as these medications are commonly a part of the standardized treatment protocols. We also estimated the incidence of NVCs identified by use of the ICD-9 codes. Despite these efforts, prophylactic use of NVC medications may not be completely controlled, resulting in potential overestimation of NVC medication use.
To minimize the risk of constipation, many guidelines and institutional treatment plans recommend prophylaxis for NVC in cancer patients, terminally ill patients, or surgical patients receiving opioids. 6, 36, 48 Thus, with the sizeable percentages of cancer and surgery patients in this study, it is possible that the actual incidence of NVC medications administered for treatment was underestimated. Patients who received NVC medications during the 6-month period before initiation of analgesics were excluded to omit patients who received NVC medications prophylactically, but analgesic-induced nausea/vomiting may have occurred in some of these patients. Patients Results of log rank test for the differences in time to medication use for NVC among four study groups was p<0.0001 who received medication for constipation on the first day of treatment with analgesics were also excluded, because it was assumed these patients received these medications as prophylaxis. This might have excluded patients who did indeed develop constipation on the first day of analgesic therapy, as some patients have reported constipation after the first dose of an opioid analgesic and opioid-induced constipation may occur despite prophylactic use of laxatives. 43, 49 In summary, more than half of hospitalized patients treated with analgesics in this study received an NVC medication, and patients treated with injectable opioid analgesics received an NVC medication more frequently than patients treated with other analgesics. Patients who received NVC medications had a longer length of stay and higher treatment costs. Thus, development of an alternative therapy for treatment of pain that minimizes common analgesic-induced adverse effects such as NVC has the potential to reduce the related economic burden on the healthcare system while improving patient outcomes.
